Praxbind

Chemical Nameidarucizumab
Dosage FormInjection (intravenous; 2.5 g/50 mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyBoehringer Ingelheim
Approval Year2015

Indication

  • For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Praxbind (idarucizumab) Prescribing Information2018Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT